

Fabiola Traina

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9220203/fabiola-traina-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144
papers

2,864
citations

27
h-index

48
g-index

150
ext. papers

3,286
ext. citations

4.2
avg, IF

4.79
L-index

#	Paper	IF	Citations
144	Phenformin increases early hematopoietic progenitors in the Jak2 murine model.. <i>Investigational New Drugs</i> , 2022 , 1	4.3	
143	Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2 driven cells.. <i>Toxicology in Vitro</i> , 2022 , 105384	3.6	
142	STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. <i>Investigational New Drugs</i> , 2021 , 1	4.3	
141	A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?. <i>Leukemia and Lymphoma</i> , 2021 , 62, 147-157	1.9	3
140	MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model. <i>Cell Death and Disease</i> , 2021 , 12, 371	9.8	2
139	New germline GATA1 variant in females with anemia and thrombocytopenia. <i>Blood Cells, Molecules, and Diseases</i> , 2021 , 88, 102545	2.1	0
138	Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation. <i>Small GTPases</i> , 2021 , 12, 20-26	2.7	2
137	Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. <i>Scientific Reports</i> , 2021 , 11, 1675	4.9	0
136	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. <i>Investigational New Drugs</i> , 2021 , 39, 736-746	4.3	2
135	Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. <i>Cellular Oncology (Dordrecht)</i> , 2021 , 44, 1105-1117	7.2	3
134	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. <i>Blood Advances</i> , 2020 , 4, 2339-2350	7.8	7
133	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. <i>Scientific Reports</i> , 2020 , 10, 10315	4.9	3
132	NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2-positive myeloproliferative neoplasm cells. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 5	21	15
131	Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. <i>Blood</i> , 2020 , 135, 870-875	2.2	26
130	Co-occurrence of BCR-ABL1-positive chronic myeloid leukaemia and CALR-mutated essential thrombocythaemia. <i>British Journal of Haematology</i> , 2020 , 188, e21-e23	4.5	2
129	Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia. <i>Cellular Oncology (Dordrecht)</i> , 2020 , 43, 1191-1201	7.2	2
128	Acquired Angioedema due to C1 Inhibitor Deficiency Preceding Splenic Marginal Zone Lymphoma: Further Insights from Clinical Practice. <i>International Archives of Allergy and Immunology</i> , 2020 , 181, 941-946	3.7	1

127	Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2 cells. <i>Investigational New Drugs</i> , 2020 , 38, 733-745	4.3	5
126	Telomere dynamics and hematopoietic differentiation of human DKC1-mutant induced pluripotent stem cells. <i>Stem Cell Research</i> , 2019 , 40, 101540	1.6	8
125	IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. <i>Cancer Letters</i> , 2019 , 456, 59-68	9.9	18
124	PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. <i>Cancer Genetics</i> , 2019 , 233-234, 56-66	2.3	5
123	Reversine exhibits antineoplastic activity in JAK2-positive myeloproliferative neoplasms. <i>Scientific Reports</i> , 2019 , 9, 9895	4.9	8
122	Metformin Suppress Cellular and Molecular Processes Related to Maintenance and Proliferation of Myeloproliferative Neoplasm Stem Cell. <i>Blood</i> , 2019 , 134, 1682-1682	2.2	1
121	Metformin exerts multitarget antileukemia activity in JAK2-positive myeloproliferative neoplasms. <i>Cell Death and Disease</i> , 2018 , 9, 311	9.8	11
120	Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study. <i>Hematology</i> , 2018 , 23, 676-682	2.2	7
119	IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. <i>Hematology, Transfusion and Cell Therapy</i> , 2018 , 40, 92-95	1.6	
118	The U2AF homology motif kinase 1 (UHMK1) is upregulated upon hematopoietic cell differentiation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 959-966	6.9	3
117	Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation. <i>Hematology, Transfusion and Cell Therapy</i> , 2018 , 40, 120-131	1.6	16
116	IRS2 (insulin receptor substrate 2). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2018 ,	2.3	1
115	Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. <i>Clinics</i> , 2018 , 73, e5662.3	2.3	12
114	De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. <i>Scientific Reports</i> , 2017 , 7, 40707	4.9	19
113	Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome. <i>Journal of Clinical Pathology</i> , 2017 , 70, 435-442	3.9	13
112	Expansion strategies for human mesenchymal stromal cells culture under xeno-free conditions. <i>Biotechnology Progress</i> , 2017 , 33, 1358-1367	2.8	28
111	Characterization of Human AB Serum for Mesenchymal Stromal Cell Expansion. <i>Transfusion Medicine and Hemotherapy</i> , 2017 , 44, 11-21	4.2	16
110	Stathmin 1 expression in plasma cell neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017 , 39, 183-185		

109	IRS1/β-Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells. <i>Journal of Cellular Biochemistry</i> , 2017 , 118, 1774-1781	4.7	12
108	Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells. <i>Heliyon</i> , 2017 , 3, e00405	3.6	6
107	Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017 , 39, 379-384		1
106	Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017 , 1863, 450-461	6.9	18
105	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. <i>Blood Advances</i> , 2017 , 1, 86-89	7.8	78
104	Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country. <i>Blood Advances</i> , 2017 , 1, 80-83	7.8	78
103	Tissue factor-dependent coagulation activation by heme: A thromboelastometry study. <i>PLoS ONE</i> , 2017 , 12, e0176505	3.7	13
102	BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine. <i>Haematologica</i> , 2016 , 101, e445-e448	6.6	13
101	Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. <i>Diagnostic Pathology</i> , 2016 , 11, 28	3	10
100	Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis. <i>Blood Cells, Molecules, and Diseases</i> , 2016 , 60, 74-7	2.1	4
99	Loss of long noncoding RNA FOXF1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells. <i>Oncotarget</i> , 2016 , 7, 68339-68349	3.3	54
98	CATS (FAM64A) abnormal expression reduces clonogenicity of hematopoietic cells. <i>Oncotarget</i> , 2016 , 7, 68385-68396	3.3	14
97	IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. <i>Oncotarget</i> , 2016 , 7, 6948-59	3.3	12
96	Hypercoagulability and Sickle Cell Disease 2016 , 109-127		
95	Pharmacological IRS1/2 Inhibition Induces Apoptosis in BCR-ABL1T315I mutant Cells. <i>Blood</i> , 2016 , 128, 1886-1886	2.2	
94	Nuclear SET Domain (NSD) Protein Lysine Methyltransferases (KMT) Family Members Expression in Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 5097-5097	2.2	
93	Reversine triggers mitotic catastrophe and apoptosis in K562 cells. <i>Leukemia Research</i> , 2016 , 48, 26-31	2.7	11
92	Reactive oxygen species overload promotes apoptosis in JAK2V617F-positive cell lines. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016 , 38, 179-81		2

91	Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016 , 38, 368-370		1
90	Metaphase cytogenetics and single nucleotide polymorphism arrays in myeloid malignancies. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015 , 37, 71-2		2
89	Differential profile of PIP4K2A expression in hematological malignancies. <i>Blood Cells, Molecules, and Diseases</i> , 2015 , 55, 228-35	2.1	5
88	Fetal hemoglobin and hemolysis markers in sickle cell anemia. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015 , 37, 148-9		2
87	Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia. <i>European Journal of Cancer</i> , 2015 , 51, 2076-85	7.5	17
86	Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015 , 37, 211-4		2
85	Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015 , 1853, 388-95	4.9	8
84	Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea. <i>Haematologica</i> , 2015 , 100, 730-9	6.6	27
83	Abnormal Hedgehog pathway in myelodysplastic syndrome and its impact on patients' outcome. <i>Haematologica</i> , 2015 , 100, e491-3	6.6	10
82	Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors. <i>Diagnostic Pathology</i> , 2015 , 10, 44	3	12
81	Elevated hypercoagulability markers in hemoglobin SC disease. <i>Haematologica</i> , 2015 , 100, 466-71	6.6	22
80	ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015 , 1853, 583-93	4.9	17
79	Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2015 , 94, 413-8	3.8	17
78	Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. <i>Oncotarget</i> , 2015 , 6, 29573-84	3.3	16
77	Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome. <i>Blood Transfusion</i> , 2015 , 13, 53-8	3.6	16
76	Compound heterozygous RAG2 mutations mimicking hyper IgM syndrome. <i>Journal of Clinical Immunology</i> , 2014 , 34, 7-9	5.7	3
75	Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. <i>Leukemia Research</i> , 2014 , 38, 251-7	2.7	25
74	Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1861-9	1.9	6

73	Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. <i>Leukemia Research</i> , 2014 , 38, 1245-51	2.7	38
72	Pyrimidine-5'-nucleotidase Campinas, a new mutation (p.R56G) in the NT5C3 gene associated with pyrimidine-5'-nucleotidase type I deficiency and influence of Gilbert's Syndrome on clinical expression. <i>Blood Cells, Molecules, and Diseases</i> , 2014 , 53, 246-52	2.1	1
71	ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. <i>Experimental Cell Research</i> , 2014 , 324, 137-45	4.2	37
70	CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12. <i>PLoS ONE</i> , 2014 , 9, e85926	3.7	37
69	Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014 , 36, 442-4		1
68	Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion. <i>Stem Cells and Development</i> , 2014 , 23, 1109-20	4.4	5
67	YAP1 expression in myelodysplastic syndromes and acute leukemias. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2413-5	1.9	8
66	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. <i>Leukemia</i> , 2014 , 28, 78-87	10.7	226
65	Endothelial activation by platelets from sickle cell anemia patients. <i>PLoS ONE</i> , 2014 , 9, e89012	3.7	30
64	Stathmin 1 in normal and malignant hematopoiesis. <i>BMB Reports</i> , 2014 , 47, 660-5	5.5	30
63	FMNL1 promotes proliferation and migration of leukemia cells. <i>Journal of Leukocyte Biology</i> , 2013 , 94, 503-12	6.5	32
62	IL10 inversely correlates with the percentage of CD8+ cells in MDS patients. <i>Leukemia Research</i> , 2013 , 37, 541-6	2.7	13
61	Altered red cell and platelet adhesion in hemolytic diseases: Hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease. <i>Clinical Biochemistry</i> , 2013 , 46, 1798-803	3.5	17
60	MDR-1 and GST polymorphisms are involved in myelodysplasia progression. <i>Leukemia Research</i> , 2013 , 37, 970-3	2.7	6
59	ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013 , 1832, 365-74	6.9	39
58	Low expression of tissue inhibitor of metalloproteinase-2 may be associated with high-risk myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1091-3	1.9	1
57	Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2013 , 98, 107-13	6.6	65
56	A case of mistaken identity: When lupus masquerades as primary myelofibrosis. <i>SAGE Open Medical Case Reports</i> , 2013 , 1, 2050313X13498709	0.7	2

55	SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. <i>Haematologica</i> , 2013 , 98, e105-7	6.6	11
54	Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores. <i>PLoS ONE</i> , 2013 , 8, e81048	3.7	20
53	PTK2 and PTPN11 expression in myelodysplastic syndromes. <i>Clinics</i> , 2013 , 68, 1371-5	2.3	
52	Downregulation of IRS2 in myelodysplastic syndrome: a possible role in impaired hematopoietic cell differentiation. <i>Leukemia Research</i> , 2012 , 36, 931-5	2.7	9
51	Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 4	22.4	16
50	Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1967-70	15.4	33
49	Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease. <i>British Journal of Haematology</i> , 2012 , 158, 788-97	4.5	25
48	Post-translational modification of the RhoGTPase activating protein 21, ARHGAP21, by SUMO2/3. <i>FEBS Letters</i> , 2012 , 586, 3522-8	3.8	8
47	SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. <i>Leukemia</i> , 2012 , 26, 542-5	10.7	178
46	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. <i>Blood</i> , 2012 , 120, 3173-86	2.2	152
45	Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients. <i>Leukemia Research</i> , 2012 , 36, 1300-3	2.7	15
44	Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome. <i>Neoplasma</i> , 2012 , 59, 530-5	3.3	4
43	Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. <i>PLoS ONE</i> , 2012 , 7, e43090	3.7	85
42	Platelets From Sickle Cell Disease Individuals Induce Endothelial Activation, Demonstrating ICAM-1 and E-Selectin Adhesion Molecule Expression, Inflammatory Cytokine Production and Activation of NF κ B Transcription Factor Gene Expression.. <i>Blood</i> , 2012 , 120, 2114-2114	2.2	
41	ANKHD1 Interacts with the Proapoptotic Protein SIVA and Plays a Role in the Proliferation and Stathmin Activation of Acute Leukemia Cells.. <i>Blood</i> , 2012 , 120, 2419-2419	2.2	
40	Low bone mass density is associated with hemolysis in Brazilian patients with sickle cell disease. <i>Clinics</i> , 2011 , 66, 801-5	2.3	22
39	Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011 , 1813, 1404-1419	14.9	22
38	Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. <i>Cancer Cell</i> , 2011 , 20, 357-69	24.3	68

37	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. <i>Blood</i> , 2011 , 118, 3932-41	2.2	265
36	Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals. <i>Inflammation Research</i> , 2011 , 60, 633-42	7.2	18
35	Updates in cytogenetics and molecular markers in MDS. <i>Current Hematologic Malignancy Reports</i> , 2011 , 6, 126-35	4.4	35
34	Clofarabine for myelodysplastic syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1005-14	5.9	
33	Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: induction of IL-10 expression in the stromal layers. <i>Leukemia Research</i> , 2011 , 35, 1102-7	2.7	9
32	Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. <i>Haematologica</i> , 2011 , 96, 526-33	6.6	30
31	Deficiência de ferro no paciente submetido à ressecção gástrica ou intestinal: prevalência, causas, repercussões clínicas, abordagem diagnóstica e prevenção. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2010 , 32, 78-83		4
30	Increased adhesive properties of platelets in sickle cell disease: roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity. <i>British Journal of Haematology</i> , 2010 , 149, 280-8	4.5	24
29	Increased expression of APAF-1 in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia. <i>European Journal of Haematology</i> , 2010 , 84, 525-30	3.8	5
28	Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts. <i>BMC Medical Genomics</i> , 2010 , 3, 30	3.7	13
27	The impact of several phenotypic features at diagnosis on survival of patients with myelodysplastic syndromes. <i>Neoplasma</i> , 2010 , 57, 530-6	3.3	7
26	New TET2, ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders. <i>Blood</i> , 2010 , 116, 3076-3076	2.2	
25	Formin-Like 1 (FMNL1) Associates with Rac1 and Negatively Regulates Neoplastic Growth and Migration in Leukemia Cell Lines.. <i>Blood</i> , 2010 , 116, 1030-1030	2.2	
24	IRS2 Is Downregulated In Primary MDS Cells and During MDS Erythroid Differentiation. <i>Blood</i> , 2010 , 116, 1886-1886	2.2	
23	Knockdown of Insulin Receptor Substrate 1 (IRS1); a Partner of BCR-ABL, Results In Decrease In Proliferation and Downregulation of AKT/mTOR and MAPK Pathways In K562 Cells. <i>Blood</i> , 2010 , 116, 4459-4459	2.2	
22	Variation of bone marrow CD34+ cell subsets in myelodysplastic syndromes according to who types. <i>Neoplasma</i> , 2009 , 56, 435-40	3.3	7
21	Inhibition of Phosphodiesterase 9A (PDE9A) Significantly Reduces Cytokine-Stimulated Adhesion of Neutrophils From Sickle Cell Disease Individuals, in Vitro, but Not Red Cell Adhesion.. <i>Blood</i> , 2009 , 114, 1520-1520	2.2	
20	Hydroxyurea Therapy Is Associated with Decreased Platelet Aggregation Responses and Activation in Sickle Cell Disease.. <i>Blood</i> , 2009 , 114, 2565-2565	2.2	

19	Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. <i>Bone Marrow Transplantation</i> , 2008 , 41, 887-93	4.4	17
18	High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils. <i>British Journal of Haematology</i> , 2008 , 142, 836-44	4.5	25
17	ANKHD1, a New Ankyrin-Repeat Protein, Binds to SIVA and May Modulate ROS Generation, Cell Cycle and Apoptosis Signaling in Cancer Cells. <i>Blood</i> , 2008 , 112, 5319-5319	2.2	
16	Reduced expression of FLIP SHORT in bone marrow of low risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2007 , 31, 853-7	2.7	4
15	Inhibition of caspase-dependent spontaneous apoptosis via a cAMP-protein kinase A dependent pathway in neutrophils from sickle cell disease patients. <i>British Journal of Haematology</i> , 2007 , 139, 148-58	4.5	20
14	Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease. <i>European Journal of Haematology</i> , 2007 , 79, 330-7	3.8	29
13	Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. <i>European Journal of Haematology</i> , 2007 , 78, 144-51	3.8	34
12	Chronic liver abnormalities in sickle cell disease: a clinicopathological study in 70 living patients. <i>Acta Haematologica</i> , 2007 , 118, 129-35	2.7	22
11	ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2006 , 1762, 828-34	6.9	28
10	Indicações de transplante de células-tronco hematopoiéticas para pacientes com diagnóstico de síndromes mielodisplásicas. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2006 , 28, 221		
9	High expression of FMNL1 protein in T non-Hodgkin's lymphomas. <i>Leukemia Research</i> , 2006 , 30, 735-8	2.7	24
8	Altered Red Cell and Platelet Adhesion in the Hemolytic Diseases: Hereditary Spherocytosis, Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Anemia.. <i>Blood</i> , 2006 , 108, 1238-1238	2.2	
7	Characterisation of a new splice variant of MASK-BP3(ARF) and MASK human genes, and their expression patterns during haematopoietic cell differentiation. <i>Gene</i> , 2005 , 363, 113-22	3.8	2
6	Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. <i>Bone Marrow Transplantation</i> , 2005 , 35, 277-82	4.4	39
5	High Expression of Human Leukocyte Formin Protein in T Non-Hodgkin's Lymphomas and in CD19 ⁺ Cell Population of Normal Tonsils.. <i>Blood</i> , 2005 , 106, 4662-4662	2.2	
4	Human leukocyte formin: a novel protein expressed in lymphoid malignancies and associated with Akt. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 311, 365-71	3.4	40
3	BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. <i>FEBS Letters</i> , 2003 , 535, 17-22	3.8	26
2	The prognostic relevance of apoptosis-related proteins in classical Hodgkin's lymphomas. <i>Leukemia and Lymphoma</i> , 2003 , 44, 483-8	1.9	19

- 1 Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience. *Sao Paulo Medical Journal*, **2000**, 118, 173-8 1.6 11